Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15265438 | 0.88 | CYP4F2 (0.37) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL19204904 | 0.88 | CYP4F2 (0.39) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL27074993 | 0.85 | GAA (0.40) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL30713479 | 0.85 | CYP4F2 (0.40) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL30713609 | 0.82 | CYP4F2 (0.31) | CYP4F2CYP4A11RET | |
| SCHEMBL28484352 | 0.81 | CYP4F2 (0.38) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL22160374 | 0.81 | CYP4F2 (0.35) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL30300121 | 0.81 | CYP4F2 (0.38) | CYP4F2CYP4A11RETRXRARXRB | |
| SCHEMBL31539796 | 0.81 | CYP4F2 (0.35) | CYP4F2CYP4A11RETALDH1A1POLB | |
| SCHEMBL31484933 | 0.80 | CYP4F2 (0.39) | CYP4F2CYP4A11RETRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-111032656-B | Heterocyclic compound kinase inhibitor and pharmaceutical composition and application thereof | 捷思英达医药技术（上海）有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| EP-3672973-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS Innopharm (Shanghai) Ltd. (CN) | 2020-07-01 | — | — | EP | disclosed |
| CN-111032656-A | Heterocyclic compound kinase inhibitor and pharmaceutical composition and application thereof | 捷思英达医药技术（上海）有限公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019037640-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019037640-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | MAP3K20, MAP3K19, MAP3K1 | CYP4F2 1915/4885CYP4A11 1071/4885RET 156/4885 |
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | CYP4F2 184/4885CYP4A11 38/4885RET 4606/4885 |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | MAP3K20, MAP3K19, MAP3K1 | CYP4F2 1915/4885CYP4A11 1071/4885RET 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.